Penumbra Inc
NYSE:PEN

Watchlist Manager
Penumbra Inc Logo
Penumbra Inc
NYSE:PEN
Watchlist
Price: 315 USD 1.8% Market Closed
Market Cap: 12.3B USD

Penumbra Inc
Total Current Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Penumbra Inc
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Penumbra Inc
NYSE:PEN
Total Current Liabilities
$169.6m
CAGR 3-Years
7%
CAGR 5-Years
9%
CAGR 10-Years
20%
Becton Dickinson and Co
NYSE:BDX
Total Current Liabilities
$8.3B
CAGR 3-Years
2%
CAGR 5-Years
7%
CAGR 10-Years
7%
Boston Scientific Corp
NYSE:BSX
Total Current Liabilities
$5.3B
CAGR 3-Years
15%
CAGR 5-Years
10%
CAGR 10-Years
9%
Stryker Corp
NYSE:SYK
Total Current Liabilities
$7.4B
CAGR 3-Years
17%
CAGR 5-Years
10%
CAGR 10-Years
8%
Abbott Laboratories
NYSE:ABT
Total Current Liabilities
$14.6B
CAGR 3-Years
3%
CAGR 5-Years
7%
CAGR 10-Years
5%
Intuitive Surgical Inc
NASDAQ:ISRG
Total Current Liabilities
$2.3B
CAGR 3-Years
23%
CAGR 5-Years
21%
CAGR 10-Years
17%
No Stocks Found

Penumbra Inc
Glance View

In the bustling landscape of medical technology, Penumbra Inc., founded in 2004, has etched a significant footprint by concentrating on an often-underexplored niche: therapies for neurovascular and peripheral vascular diseases. The company began its journey focusing primarily on devices to treat conditions like strokes, introducing its first product, the Penumbra System, swiftly after its inception. By innovating in thrombectomy techniques, Penumbra has provided interventionalists with the tools to effectively remove clots in the brain and restore blood flow, a crucial factor in minimizing stroke damage. The firm's pioneering spirit and commitment to addressing the unmet needs in the medical field have propelled its growth, driven by an unyielding focus on enhancing clinical outcomes for patients facing critical vascular conditions. Penumbra's success hinges not just on innovative product development but also on a comprehensive business model that centers around high-impact therapeutic solutions. It generates revenue through the sale of these specialized medical devices, primarily to hospitals and healthcare facilities across the globe. By leveraging cutting-edge technology and collaboration with healthcare professionals, Penumbra continually broadens its product portfolio, including devices for peripheral vascular interventions and embolization therapies. This focus on expanding clinical applications and adapting to emerging medical challenges ensures that Penumbra stays at the forefront of innovation, enabling it to capture a growing share of the global healthcare market. Through its focused approach, Penumbra not only makes strides in advancing medical treatments but also fortifies its position as a formidable player in the field of therapeutic medical devices.

PEN Intrinsic Value
135.92 USD
Overvaluation 57%
Intrinsic Value
Price

See Also

What is Penumbra Inc's Total Current Liabilities?
Total Current Liabilities
169.6m USD

Based on the financial report for Sep 30, 2025, Penumbra Inc's Total Current Liabilities amounts to 169.6m USD.

What is Penumbra Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
20%

Over the last year, the Total Current Liabilities growth was 11%. The average annual Total Current Liabilities growth rates for Penumbra Inc have been 7% over the past three years , 9% over the past five years , and 20% over the past ten years .

Back to Top